AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine



VIENNA, July 24, 2014 /PRNewswire via COMTEX/ -- VIENNA, July 24, 2014 /PRNewswire/ --

What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community.



When: Thursday, July 31, 2014

11.00 am EST (Eastern Standard Time)

03.00 pm UTC (Coordinated Universal Time)



Where: New York Marriott East Side Hotel

525 Lexington Ave, New York

Room Morgan A

Live webcast link: http://totalwebcasting.com/view/?id=affiris



Who: Walter Schmidt, PhD: CEO & Co-founder, AFFiRiS AG

Todd Sherer, PhD: CEO, The Michael J. Fox Foundation

Prof. Achim Schneeberger, MD: CMO, AFFiRiS AG



If you are unable to attend the press conference, please visit the aforementioned web link for a live webcast. An embedded message board will allow you to participate in the Q&A. A recording of the conference will be made available immediately after the press conference at http://totalwebcasting.com/view/?id=affiris

About AFFiRiS AG

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria ( http://www.affiris.com ).

http://www.marketwatch.com/story/med...ine-2014-07-24

Badboy, thanks for posting the link. I'll be at the presentation and I'm very interested in seeing the early results. The vaccine still has a long way to go, but it could be a breakthrough development if it works.

Please give us a full report on anything you hear that's not broadcast. Thank you.

AffiRis presented very promising Phase I results today of it's a-syn vaccine, PD01A. The safety profile (the real purpose of this phase) was excellent. The non-serious adverse events were evenly distributed among the test groups and control. There were three serious adverse events over the year and none were attributed to the drug.

With regard to preliminary efficacy, the two test groups remained stable throughout the year while the placebo group had deterioration. Even with the small sample sizes the results were significant.

Interesting, not all of the test group subjects actually reacted to the vaccine with a buildup of a-syn antibodies. Only about half of the test group had antibodies in serum samples. When analyzed for only those that had the antibodies, the results much more evident.

The company intends to begin the next study immediately. They are considering adding on locations in the US (they are located in Austria).

Press Release:

http://www.affiris.com/html/en/press...meldungen.html

crossing my fingers. pretty small group.

I have high hopes. It's past 11am Eastern time??

Check out the slides once they are live.

It was, but phase I usually is. Not sure you could have had any better results other than the possibility that only some PwP will react to the vaccine. It will be interesting to see how they explain that, and if they can reconfigure for others.

Presentation should be available for rebroadcast shortly (including slides). If not, I have copies and can PM to anyone who wants them.

i assume MJFF will do a webinar to put things in perspective?